公开(公告)号：WO2020257544A1

公开(公告)日：2020-12-24

申请号：PCT/US2020/038568

申请日：2020-06-19

Applicant: THE POPULATION COUNCIL, INC.

Inventor： VARIANO, Bruce

IPC: A61K9/00 ,  A61K31/567 ,  A61K31/57 ,  A61P15/18 ,  A61F6/06

Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.

公开(公告)号：WO2011049948A3

公开(公告)日：2011-06-16

申请号：PCT/US2010053201

申请日：2010-10-19

Applicant: POPULATION COUNCIL INC ,  SITRUK-WARE REGINE ,  SCHUMACHER MICHAEL MARIA HELMUT ,  BRINTON ROBERTA ,  EL-ETR MARTINE ,  GHOUMARI ABDELMOUMAN ,  GUENNOUN RACHIDA

Inventor： SITRUK-WARE REGINE ,  SCHUMACHER MICHAEL MARIA HELMUT ,  BRINTON ROBERTA ,  EL-ETR MARTINE ,  GHOUMARI ABDELMOUMAN ,  GUENNOUN RACHIDA

IPC: A61K31/00 ,  A61K31/565 ,  A61K31/57 ,  A61K31/573 ,  A61K31/575 ,  A61K31/585 ,  A61K45/06 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28

CPC classification number: A61K31/565 ,  A61K31/00 ,  A61K31/57 ,  A61K31/573 ,  A61K31/575 ,  A61K31/585 ,  A61K45/06

Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17a-acetoxy-19-norpregn-4-ene-3, 20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.

Abstract translation: 公开了用于治疗患者神经变性和/或髓鞘形成的方法，其包括用与孕酮受体结合的孕激素化合物治疗患者，并引发孕激素受体诱导的生物反应而不与雄激素受体相互作用并且不诱导雄激素或糖皮质激素生物反应 足以预防或减少神经变性的剂量。 孕激素化合物优选包含16-亚甲基-179-乙酰氧基-19-去甲孕-4-烯-3,20-二酮，并且所述方法包括将孕激素化合物与雌激素化合物组合以提供髓鞘修复和神经变性的避孕和治疗 。

公开(公告)号：WO2011049948A2

公开(公告)日：2011-04-28

申请号：PCT/US2010/053201

申请日：2010-10-19

Applicant: THE POPULATION COUNCIL, INC. ,  SITRUK-WARE, Regine ,  SCHUMACHER, Michael, Maria Helmut ,  BRINTON, Roberta ,  EL-ETR, Martine ,  GHOUMARI, Abdelmouman ,  GUENNOUN, Rachida

Inventor： SITRUK-WARE, Regine ,  SCHUMACHER, Michael, Maria Helmut ,  BRINTON, Roberta ,  EL-ETR, Martine ,  GHOUMARI, Abdelmouman ,  GUENNOUN, Rachida

IPC: A61K31/00 ,  A61K31/565 ,  A61K31/57 ,  A61K31/573 ,  A61K31/575 ,  A61K31/585 ,  A61K45/06 ,  A61P25/28 ,  A61P25/16 ,  A61P25/00

CPC classification number: A61K31/565 ,  A61K31/00 ,  A61K31/57 ,  A61K31/573 ,  A61K31/575 ,  A61K31/585 ,  A61K45/06

Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17α-acetoxy-19-norpregn-4-ene-3, 20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.

Abstract translation: 公开了用于治疗患者的神经变性和/或髓鞘化的方法，包括用孕酮化合物治疗患者，所述孕酮化合物发挥与孕酮受体的结合并引发黄体酮 - 受体 - 诱导的生物反应而不与雄激素受体相互作用，和 而没有以足以预防或减少神经变性的剂量诱导雄激素或糖皮质激素生物学应答。 孕激素化合物优选包含16-亚甲基-17α-乙酰氧基-19-降孕-4-烯-3,20-二酮，所述方法包括将孕激素化合物与雌激素化合物组合以提供避孕和治疗髓磷脂修复和神经变性

公开(公告)号：WO2003093322A2

公开(公告)日：2003-11-13

申请号：PCT/US2003/013456

申请日：2003-04-30

Applicant: THE POPULATION COUNCIL, INC. ,  FMC CORPORATION ,  MAGUIRE, Robin, A. ,  THORN, Mitchell ,  PHILLIPS, David, M. ,  BLAKEMORE, William, R. ,  BALLARD, Arthur, D. ,  SEWALL, Christopher, J. ,  MODLISZEWSKI, James, J. ,  BUBNIS, William, A.

Inventor： MAGUIRE, Robin, A. ,  THORN, Mitchell ,  PHILLIPS, David, M. ,  BLAKEMORE, William, R. ,  BALLARD, Arthur, D. ,  SEWALL, Christopher, J. ,  MODLISZEWSKI, James, J. ,  BUBNIS, William, A.

IPC: C08B

CPC classification number: C08L5/00 ,  A01N59/16 ,  A61K9/0031 ,  A61K9/0034 ,  A61K31/57 ,  A61K31/715 ,  A61K31/731 ,  A61K33/30 ,  A61K33/34 ,  A61K33/38 ,  A61K45/06 ,  C08B37/0042 ,  C08L5/12 ,  A61K2300/00 ,  A01N25/10 ,  A01N2300/00

Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contains one or more carrageenans, including lambda carrageenan. Also disclosed are methods for making and using the compositions.

Abstract translation: 公开了抑制含有一种或多种角叉菜胶（包括λ角叉菜胶）的性传播感染传播的组合物。 还公开了制备和使用组合物的方法。

公开(公告)号：WO1998008471A1

公开(公告)日：1998-03-05

申请号：PCT/US1997006570

申请日：1997-04-18

Applicant: THE POPULATION COUNCIL, INC. ,  MOO-YOUNG, Alfred, J. ,  CROXATTO-AVONI, Horacio, B. ,  JACKANICZ, Theodore, M. ,  SALVATIERRA MARTINEZ, Ana Maria

Inventor： THE POPULATION COUNCIL, INC.

IPC: A61F06/06

CPC classification number: A61K31/569 ,  A61F6/06 ,  A61K9/0036 ,  A61K9/0039 ,  A61K31/567 ,  A61K31/575

Abstract: The delivery of an antiprogestin in low dose amounts either vaginally or in the uterus is used as a contraceptive.

Abstract translation: 以阴道或子宫中的低剂量量递送抗孕激素作为避孕药。

公开(公告)号：WO1997030656A1

公开(公告)日：1997-08-28

申请号：PCT/US1997002798

申请日：1997-02-21

Applicant: THE POPULATION COUNCIL, INC.

Inventor： THE POPULATION COUNCIL, INC. ,  MOO-YOUNG, Alfred, J. ,  SALEH, Saleh, I.

IPC: A61F02/02

CPC classification number: A61K9/0024 ,  A61K9/0092 ,  A61K31/565 ,  A61K31/568 ,  A61K31/569

Abstract: The present invention relates to implantable male contraceptive devices. An ethylene vinyl acetate copolymer based implant (10) is described for delivery of an androgen (15) and a system including an ethylene vinyl acetate copolymer based implant (10) as well as a second implant are described for the administration of both androgen and a sterilitant. These implants may be used to provide contraception for men, as well as, for hormone therapy, treatment of enlarged prostate and other ailments.

Abstract translation: 本发明涉及可植入男性避孕装置。 描述了一种用于输送雄激素（15）的乙烯 - 乙酸乙烯酯共聚物基植入物（10），包括基于乙烯 - 乙酸乙烯酯共聚物的植入物（10）以及第二种植入物的系统用于施用雄激素和 sterilitant。 这些植入物可用于为男性提供避孕措施，以及用于激素治疗，治疗前列腺增大和其他疾病。

公开(公告)号：WO2014123880A1

公开(公告)日：2014-08-14

申请号：PCT/US2014/014633

申请日：2014-02-04

Applicant: THE POPULATION COUNCIL, INC.

Inventor： ZYDOWSKY, Thomas M. ,  UGAONKAR, Shweta ,  SEIDOR, Samantha

IPC: A61K31/731 ,  A61K31/315 ,  A61K31/44

CPC classification number: A61K9/0036 ,  A61K31/44 ,  A61K31/731 ,  A61K33/30 ,  A61K47/36 ,  A61K2300/00

Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified antiretroviral agents comprising NNRTIs and NRTIs. Also disclosed are methods for making and using the compositions. Also disclosed are intravaginal rings for delivering water-soluble compounds, and preferably high molecular weight water-soluble polymers at essentially a zero order rate. The rings include an outer layer of non-water-swellable elastomer, and preferably high molecular weight water-soluble polymer and an inner layer of the water-soluble polymer, which is imbedded in the outer layer, and an aperture through the outer layer for release thereof only through that aperture.

Abstract translation: 公开了用于抑制含有一种或多种聚阴离子杀微生物剂（例如角叉菜胶，包括λ角叉菜胶）以及水溶性金属盐和包含NNRTI和NRTI的特定抗逆转录病毒剂的性传播感染传播的组合物。 还公开了制备和使用组合物的方法。 还公开了用于递送水溶性化合物的阴道内环，优选基本上为零级速率的高分子量水溶性聚合物。 这些环包括非水溶胀性弹性体的外层，优选高分子量水溶性聚合物和嵌入外层的水溶性聚合物的内层，以及穿过外层的孔 仅通过该孔径释放它。

公开(公告)号：WO2011084668A1

公开(公告)日：2011-07-14

申请号：PCT/US2010/060941

申请日：2010-12-17

Applicant: THE POPULATION COUNCIL, INC. ,  ANTARES PHARMA IPL AG ,  SITRUK-WARE, Regine ,  CARRARA, Dario Norberto, Ramon ,  GRENIER, Arnaud

Inventor： SITRUK-WARE, Regine ,  CARRARA, Dario Norberto, Ramon ,  GRENIER, Arnaud

IPC: A61K31/565 ,  A61K31/57 ,  A61K9/00 ,  A61P15/18

CPC classification number: A61K31/565 ,  A61K9/0014 ,  A61K31/57 ,  A61K2300/00

Abstract: The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses.

Abstract translation: 本发明公开了用于确保两性生育年龄的妇女的组合物和方法，其确保具有额外的健康益处的避孕措施以及绝经后妇女，其中提供具有额外医疗益处的激素疗法，例如血栓形成风险降低的潜力。 上述组合物包含NES作为无雄激素和雌激素而不是糖皮质激素作用的有效的孕激素和抗iov药，并与配制用于非口服透皮给药的雌二醇组合作为特定的日剂量。

公开(公告)号：WO2002102996A1

公开(公告)日：2002-12-27

申请号：PCT/US2002/019413

申请日：2002-06-19

Applicant: THE POPULATION COUNCIL, INC. ,  CHENG, C., Yan

Inventor： CHENG, C., Yan

IPC: C12N1/20

CPC classification number: C07K14/59 ,  A01K2217/05 ,  A61K38/1709 ,  C07K14/47 ,  C07K14/705 ,  C07K2319/00 ,  C07K2319/01

Abstract: Disclosed are male contraceptives containing a peptide and analogs thereof having an amino acid sequence corresponding to the second extracellular domain of a mammalian occludin. The peptides may be linked to a carrier targeting testicular cells, preferably to a modified follicle stimulating hormone. Methods of producing such a contraceptive, and a method of use are also disclosed.

Abstract translation: 公开了含有肽及其类似物的男性避孕药具有对应于哺乳动物闭合蛋白的第二细胞外结构域的氨基酸序列。 肽可以连接到靶向睾丸细胞的载体，优选连接到修饰的促卵泡激素。 还公开了生产这种避孕药的方法和使用方法。

公开(公告)号：WO9728187A3

公开(公告)日：1997-10-23

申请号：PCT/US9701726

申请日：1997-01-29

Applicant: POPULATION COUNCIL INC

Inventor： FONTENOT JAMES DARRELL ,  PHILLIPS DAVID M

IPC: A61K38/00 ,  C07K14/47 ,  C07K16/10 ,  A61K39/395

CPC classification number: C07K14/4727 ,  A61K38/00 ,  C07K16/1063 ,  C07K2317/34 ,  C07K2319/00

Abstract: A proline rich, tandem repeat domain of human mucin MUC1 forms an extended structure containing large repeating loops that are crested by a turn. The repeating loop structure of MUC1 can be replaced by an Φ loop of an immunoglobulin-superfamily protein to create a chimeric, multivalent, mucin-like, compound. The mucin/Φ loop chimera retains the binding specificity of the parent immunoglobulin-superfamily protein. The design and construction of chimeric peptides are general, theoretically limited only by the size of the immunoglobulin superfamily. The peptides can be used for a variety of prophylactic and therapeutic applications.